Genomewide association study of acute anterior uveitis identifies new susceptibility loci by Huang, Xiu Feng et al.
Genetics
Genomewide Association Study of Acute Anterior Uveitis
Identifies New Susceptibility Loci
Xiu-Feng Huang,1–3 Zhixiu Li,1 Erika De Guzman,1 Philip Robinson,4 Lianne Gensler,5
Michael M. Ward,6 Mohammad Hossein Rahbar,7 MinJae Lee,7 Michael H. Weisman,8
Gary J. Macfarlane,9,10 Gareth T. Jones,9,10 Eva Klingberg,11,12 Helena Forsblad-d’Elia,11,12
Peter McCluskey,13 Denis Wakefield,14 Jeff S. Coombes,15 Maria A. Fiatarone Singh,16
Yorgi Mavros,16 Nicole Vlahovich,17 David C. Hughes,17 Helena Marzo-Ortega,18,19
Irene Van der Horste-Bruinsma,20 Finbar O’Shea,21 Tammy M. Martin,23 James Rosenbaum,22
Maxime Breban,24–26 Zi-Bing Jin,27,28 Paul Leo,1 John D. Reveille,29 B. Paul Wordsworth,30
and Matthew A. Brown31,32
1Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology at
Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia
2School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
3State Key Laboratory of Optometry, Ophthalmology and Vision Science, Wenzhou, Zhejiang, China
4University of Queensland School of Clinical Medicine, Royal Brisbane Hospital, Herston Queensland, Australia
5Department of Medicine/Rheumatology, University of California San Francisco, San Francisco, California, United States
6Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of
Health, Bethesda, Maryland, United States
7Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science
Center at Houston, Houston, Texas, United States
8David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States
9Epidemiology Group, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University
of Aberdeen, Foresterhill, Aberdeen, Scotland, United Kingdom
10Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Foresterhill, Aberdeen, Scotland,
United Kingdom
11Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden
12Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg,
Gothenburg, Sweden
13Discipline of Clinical Ophthalmology and Eye Health Faculty of Medicine and Health, The University of Sydney, Sydney,
Australia
14School of Medical Sciences, University of New South Wales, Kensington, New South Wales, Australia
15School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, Australia
16Physical Activity, Lifestyle, Ageing and Wellbeing Faculty Research Group, Faculty of Health Sciences, University of
Sydney, Sydney, New South Wales, Australia
17Department of Sports Medicine, Australian Institute of Sport, Bruce, ACT, Australia
18NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
19Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
20Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
21Department of Rheumatology, St. James’s Hospital, Dublin, Ireland
22Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus,
Legacy Devers Eye Institute, both in Portland, Oregon, United States
23Departments of Ophthalmology, and Molecular Microbiology & Immunology, Oregon Health & Sciences University,
Oregon, United States
24UMR 1173, Inserm, University of Versailles Saint-Quentin, Montigny-le-Bretonneux, France
25Hôpital Ambroise Paré, AP-HP, and Université de Versailles Saint-Quentin, Boulogne-Billancourt, France
26INFLAMEX, Laboratoire d’Excellence, Université Paris Diderot, Sorbonne Paris Cité, France
27Division of Ophthalmic Genetics, The Eye Hospital, Wenzhou Medical University, Wenzhou, China
28State Key Laboratory of Ophthalmology, Optometry and Vision Science, National International Joint Research Center for
Regenerative Medicine and Neurogenetics, Wenzhou Medical University, Wenzhou, China
29Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas,
United States
30NIHR Oxford Musculoskeletal Biomedical Research Unit, Nuffield Orthopaedic Centre, Headington, Oxford,
United Kingdom
31Centre for Precision Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
32Guy’s & St Thomas’ NHS Foundation Trust and King’s College London NIHR Biomedical Research Centre, London,
United Kingdom
Copyright 2020 The Authors
iovs.arvojournals.org | ISSN: 1552-5783 1
This work is licensed under a Creative Commons Attribution 4.0 International License.
Downloaded from iovs.arvojournals.org on 05/19/2021
GWAS of AAU IOVS | June 2020 | Vol. 61 | No. 6 | Article 3 | 2
Correspondence: Matthew A. Brown,
8th Floor Tower Wing, Guy’s
Hospital, Great Maze Pond, London
SE1 9RT, England;
matt.brown@kcl.edu.au.
PURPOSE. Acute anterior uveitis (AAU) is a common intraocular inflammatory disease. AAU
occurs in 30% to 50% of patients with ankylosing spondylitis (AS), and both conditions
are strongly associated with human leukocyte antigen (HLA)-B27, implying a shared
etiology. This study aims to apply genomewide association study (GWAS) to characterize
the genetic associations of AAU and their relationship to the genetics of AS.
METHODS. We undertook the GWAS analyses in 2752 patients with AS with AAU (cases)
and 3836 patients with AS without AAU (controls). There were 7,436,415 single-
nucleotide polymorphisms (SNPs) available after SNP microarray genotyping, imputation,
and quality-control filtering.
RESULTS. We identified one locus associated with AAU at genomewide significance:
rs9378248 (P = 2.69 × 10−8, odds ratio [OR] = 0.78), lying close to HLA-B. Sugges-
tive association was observed at 11 additional loci, including previously reported AS loci
ERAP1 (rs27529, P = 2.19 × 10−7, OR = 1.22) and NOS2 (rs2274894, P = 8.22 × 10−7,
OR = 0.83). Multiple novel suggestive associations were also identified, includingMERTK
(rs10171979, P = 2.56 × 10−6, OR = 1.20), KIFAP3 (rs508063, P = 5.64 × 10−7, OR =
1.20), CLCN7 (rs67412457, P = 1.33 × 10−6, OR = 1.25), ACAA2 (rs9947182, P = 9.70
× 10−7, OR = 1.37), and 5 intergenic loci. The SNP-based heritability is approximately
0.5 for AS alone, and is much higher (approximately 0.7) for AS with AAU. Consistent
with the high heritability, a genomewide polygenic risk score shows strong power in
identifying individuals at high risk of either AS with AAU or AS alone.
CONCLUSIONS. We report here the first GWAS for AAU and identify new susceptibility loci.
Our findings confirm the strong overlap in etiopathogenesis of AAU with AS, and also
provide new insights into the genetic basis of AAU.
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Uveitis is a major cause of ocular disease, leading to 5% to10% of visual impairment worldwide.1 The prevalence
varies depending on the ethnicity and geographic locations:
115 per 100,000 in America,2 40 per 100,000 in Japan,3 and
310 to 730 per 100,000 in Southern India.4 Acute anterior
uveitis (AAU) is the most common type of uveitis and is char-
acterized by inflammation of the anterior chamber.5 The typi-
cal clinical manifestations of AAU are that of abrupt onset
of unilateral, often alternating, anterior uveitis, with signif-
icant cellular and protein extravasation into the anterior
chamber and tendency for recurrences.6 AAU is frequently
associated with spondyloarthropathies, such as ankylos-
ing spondylitis (AS), psoriatic arthritis, and inflammatory
bowel disease.7 Among those spondyloarthropathies, AS
is the most common associated condition, present in 30%
to 50% of patients with AAU. AAU is strongly associated
with human leukocyte antigen (HLA)-B27.8 A large genetic
study reported the prevalence of HLA-B27 was 81.8% in the
group with ophthalmologist-diagnosed AAU and 92.0% in
the group with self-reported AAU.9 Among patients with
AAU who are HLA-B27 positive, the prevalence of concomi-
tant AS rises to 80% to 84%.10
Multiple studies have demonstrated that genetic compo-
nents play a major role in uveitis. Derhaag et al. found that
the prevalence of AAU in HLA-B27-positive first-degree rela-
tives of patients with AAU was 13%, significantly higher
than the frequency of 1% in the HLA-B27-positive individ-
uals without affected relatives, indicating high familiality.11
Several polymorphisms have been identified to be asso-
ciated with the presence of AAU. To date, the strongest
genetic association between a genetic component and AAU
is attributable to HLA-B27, the major histocompatibility
complex (MHC) type I allele. On the basis of genotyp-
ing using the Illumina Immunochip, a comparison between
AAU and healthy control subjects found significant associa-
tion over HLA-B, corresponding to the HLA-B27 tag single-
nucleotide polymorphism (SNP) rs116488202.9 This study
also found the association of three non-MHC loci, ERAP1,
IL23R, and the intergenic region 2p15 with genomewide
significance, and five loci reached a suggestive level of
significance (IL10-IL19, IL18R1-IL1R1, IL6R, the chromo-
some 1q32 locus harboring KIF21B, and a retinal-related
gene EYS).9 The authors also demonstrated significant differ-
ences in effect size of several previously discovered AS
loci between AS+AAU+ and AS+AAU-, using two different
models. In the first model (including the SNP and principal
components), different effect sizes were observed in ERAP1,
UBE2LE, ICOSLG, and EYS. In the second model (includ-
ing the SNP, principal components, and HLA-B27 dose),
different effect sizes were observed in ERAP1, ANTXR2,
21q22, and 2p15.9 Additionally, in an analysis comparing
patients with AS with AAU versus controls, HLA-B27 and
HLA-A*0201 were strongly associated with AAU using Illu-
mina Exomechip microarray.12 Many candidate-gene asso-
ciation studies have reported nominal SNP associations in
interleukin (IL) genes, tumor necrosis factor (TNF) genes,
and complement factors correlated with anterior uveitis.13–15
However, those candidate-gene association studies were not
adequately powered to reliably identify genes involved in
AAU, nor did they control for potential population stratifica-
tion effects, and, thus, their interpretation is unclear.
Genomewide association studies (GWAS) have proven
to be a powerful and robust method to identify genetic
associations with complex diseases over the past decade.
For example, using GWAS, more than 100 AS susceptibil-
ity loci have been identified,16–20 which have been transfor-
mational in understanding the pathogenesis of AS,21,22 have
changed disease management through repositioning of IL-17
inhibitors for management of the disease,23 and have stimu-
lated several drug development programs.24 Although GWAS
have been undertaken for nearly all major immune-mediated
diseases, at this point, there have been no GWAS for AAU.
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This study aims to apply GWAS to characterize extensively
the genetic associations of AAU and their relationship to the
genetics of AS.
METHODS
Sample Collection and Genotyping
AS case and control cohorts involved in this study are
described in Supplementary Table S1. AS cases were defined
by the modified New York criteria.25 Control participants
were not specifically screened either for AS or AAU. All
patients gave written informed consent, and ethics approval
has been obtained from all relevant institutional ethics
committees.
Genotyping and Quality Control
All the individuals of European descent have been previ-
ously genotyped using Illumina Infinium HumanCoreEx-
ome 24v1.1, according to the manufacturer’s recommen-
dations. Subsequently, bead intensity data were processed
and normalized for each sample in Illumina GenomeStu-
dio software. Data for successfully genotyped samples were
extracted, and genotypes were called within collections
using GenomeStudio. The human genome build 19 was used
(UCSC).
The thresholds used in quality control include: a geno-
typing missingness rate of 0.05; an individual missingness
rate of 0.05; a Hardy-Weinberg Equilibrium (HWE) thresh-
old in controls of 1 × 10−6; a minor allele frequency (MAF)
of 0.01; heterozygosity versus missingness outliers beyond
three SDs were excluded; identity by descent (IBD) thresh-
old of PI-HAT (proportion [IBD = 2] + 0.5 [IBD = 1])
0.185 was used. Principal components analysis (PCA) was
then computed using Genome-wide Complex Trait Analysis
(GCTA) after the removal of regions of long-range linkage
disequilibrium.26 Ancestry outliers were removed by using
the top two components. A second round of PCA was then
performed to better resolve ancestry differences within the
cohorts. Principal components were used as covariates to
control for population stratification.
Imputation
Genotyping data were imputed using Sanger imputation
service (https://imputation.sanger.ac.uk/). Optional pre-
phasing was with EAGLE227 and imputation with PBWT.28
The Haplotype Reference Consortium was used as the refer-
ences panel. Imputed loci with quality score < 0.6 were
excluded from the association testing. Detailed investiga-
tions of the MHC alleles and HLA loci were performed using
SNP2HLA,29 which is an analysis package that performs HLA
allele and amino acid imputation from SNP data and associ-
ation analysis.
Association Analysis
Plink (https://www.cog-genomics.org/plink2)30 was used to
perform association analyses with eigenvectors from PCA
as covariates for population stratification control. Signifi-
cance levels were defined as genomewide (P < 5 × 10−8)
or suggestive when P > 5 × 10−8 but < 1 × 10−5. Previ-
ous reported loci were also examined. Subsequently, condi-
tional analysis for secondary signal detection was performed
in all susceptibility loci by fitting the primary SNP as a fixed
effect. Manhattan plots and quantile to quantile (Q-Q) plots
were displayed, and genomic inflation factor 1000 values
were calculated. To identify the genetic basis of AAU, we
designed the GWAS based on comparison of patients with
AS with AAU (AS+AAU+) versus patients with AS without
AAU (AS+AAU-). Locus zoom plotting was carried out using
LocusZoom.31
Estimation of SNP-Based Heritability
We estimated the SNP-based heritability (SNP h2) by GCTA.26
Heritability is the proportion of the phenotypic variance
accounted for by genetic effects. We investigated SNP-based
heritability by designing three different comparisons: (1)
patients with AS with AAU (AS+AAU+) versus patients with
AS without AAU (AS+AAU-); (2) patients with AS without
AAU (AS+AAU-) versus controls; and (3) patients with AS
with AAU (AS+AAU+) versus controls. The estimation of
heritability was performed for a range of disease preva-
lences.
Mendelian Randomization Analysis
To determine the most likely causal genes, we performed
the summary data-based Mendelian randomization (SMR32)
analysis for AAU with expression quantitative trait loci
(eQTL) data. GWAS data consisted of patients with AS
with AAU (AS+AAU+) and patients with AS without AAU
(AS+AAU-), and the eQTL data was from the Consor-
tium for the Architecture of Gene Expression (CAGE),
which comprises individual-level whole-blood expression
and genotype data on 2765 individuals.33 In the SMR analy-
sis, only probes for which the P value of the top associated
cis-eQTL was < 5 × 10−8 were included and the MHC region
was excluded. To control the genomewide type I error rate,
Bonferroni correction was used to account for multiple test-
ing. Locus zoom plots of candidate loci were generated.
Genomewide Polygenic Risk Scores
Polygenic risk scores (PRS) were calculated for each individ-
ual using the adaptive MultiBLUP algorithm.34 Only geno-
typed SNPs in common between all SNP arrays where the
missingness rate was <0.05, the MAF was >0.01, and the
HWE P value was > 1 × 10−6 were used. A conservative
approach was used whereby the cohort was divided into
independent training and test sets, rather than using a cross-
validation approach.35 The training set was then used to
calculate the scoring matrix. This MultiBLUP algorithm first
selected regions based on a P values’ threshold (option-sig1)
obtained using the training cohort. Within these regions, all
SNPs with a significance threshold greater than a second P
value threshold (option-sig2) were considered by the algo-
rithm, which then controls for the linkage disequilibrium
structure. The P value thresholds were optimized by choos-
ing a range of values between 1 × 10−7 and 1 × 10−3 for
option-sig1 and 1 × 10−3 and 1 × 10−2 for option-sig2. Then
the resulting weighted predictors were applied to the test
cohort to obtain per sample scores from which the maxi-
mum area under the curve (AUC) was obtained.
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TABLE 1. Results of the Association Analyses of Patients With AS with AAU versus patients with AS Without AAU
SNP ID Chr. Position* Nearby Genes P Value Effect Allele OR 95% CI Associated With AS
rs9378248 6p21 31326289 HLA-B 2.69 × 10−8 A 0.78 0.71-0.85 Yes
rs508063 1q24 169923676 C1orf112-SCYL3-KIFAP3 5.64 × 10−7 A 1.20 1.12-1.28 No
rs10171979 2q13 112823320 MERTK-TMEM87B 2.56 × 10−6 C 1.20 1.11-1.30 Yes
rs76412624 3p24 18186605 Intergenic 1.98 × 10−6 G 0.67 0.57-0.79 No
rs27529 5q15 96126308 ERAP1 2.19 × 10−7 A 1.22 1.13-1.31 Yes
rs7784778 7p12 46951833 Intergenic 6.22 × 10−6 T 0.84 0.78-0.91 No
rs10093384 8q21 88635942 Intergenic 7.01 × 10−6 A 1.20 1.11-1.31 No
rs67412457 16p13 1525710 CLCN7 1.33 × 10−6 A 1.25 1.14-1.36 No
rs2274894 17q11 26099171 NOS2 8.22 × 10−7 T 0.83 0.78-0.90 Yes
rs9947182 18q21 47253904 ACAA2 9.70 × 10−7 T 1.37 1.21-1.55 No
rs7281081 21q21 29471489 Intergenic 4.98 × 10−6 T 0.79 0.71-0.87 No
rs1580226 22q12 34809453 Intergenic 8.26 × 10−6 T 0.82 0.75-0.89 No
Chr., chromosome; OR, odds ratio; 95% CI, 95% confidence interval.
* UCSC, human genome build 19.
FIGURE 1. Manhattan plot of association analyses of patients with AS with AAU versus patients with AS without AAU. Y axis represents the
P values on the -log10 scale. The red line represents P = 5 × 10−8 (genomewide significance), and the blue dashed line represents P = 1
× 10−5 (suggestive association).
RESULTS
Comparison of Patients With AS With AAU versus
AS Alone
To investigate the genetic basis of AAU while controlling for
concomitant AS, we performed a GWAS comparing patients
with AS with AAU (AS+AAU+) versus patients with AS with-
out AAU (AS+AAU-). After individual quality control (QC)
there were 2752 patients with AS and with AAU and 3836
patients with AS alone, respectively. Given our sample size,
the study has > 80% power for risk alleles of MAF = 0.2,
for heterozygote odds ratios (ORs) > 1.21 at a type 1 error
rate of 5 × 10−8. After imputation and SNP QC, there were
7,436,415 SNPs (Supplementary Table S2). Subsequently,
analysis of logistic regression with principal components as
covariates against linear mixed models was conducted. The
top four eigenvectors were controlled because additional
eigenvectors did not reduce the genomic inflation factor.
Quantile to quantile (Q-Q) plots are presented in Supple-
mentary Figure S1. Genomic inflation factor (λ) calculated
using 7,396,528 SNPs (MHC SNPs were excluded) was 1.008
(λ1000 for an equivalent study of 1000 cases and 1000 controls
= 1.002), indicating minimal evidence of residual population
stratification in the overall data set. Genomic inflation factors
stratified by frequency, imputation quality score, and MHC
are shown in Supplementary Table S3.
We identified one locus associated with AAU at
genomewide significance: rs9378248 (P = 2.69 × 10−8,
OR = 0.78), lying close to HLA-B, a known susceptibility
gene for both AAU and AS (Table 1 and Fig. 1). Suggestive
association was observed at 11 additional loci summarized
in Table 1. We found suggestive association with SNPs in
MERTK locus (rs10171979, P = 2.56 × 10−6, OR = 1.20),
which is also a novel finding in our ongoing GWAS in
AS (Table 1 and Fig. 2a). Association was also observed
with SNPs at previously reported AS loci, including ERAP1
(rs27529, P = 2.19 × 10−7, OR = 1.22; Fig. 2b), and NOS2
(rs2274894, P = 8.22 × 10−7, OR = 0.83; Fig. 2c).
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FIGURE 2. Locus zoom plot of association results for MERTK-
TMEM87B locus (a), ERAP1 locus (b), and NOS2 locus (c). The
reference population for LD data is 1000 Genomes EUR. SNPs with
missing LD information are shown in grey.
In addition to these discoveries, association was seen at
loci not previously known to be associated with AAU or AS,
including KIFAP3 (rs508063, P = 5.64 × 10−7, OR = 1.20),
CLCN7 (rs67412457, P = 1.33 × 10−6, OR = 1.25), ACAA2
(rs9947182, P = 9.70 × 10−7, OR = 1.37), and five intergenic
loci at 3p24 (rs76412624, P = 1.98 × 10−6, OR = 0.67), 7p12
(rs7784778, P = 6.22 × 10−6, OR = 0.84), 8q21 (rs10093384,
P = 7.01 × 10−6, OR = 1.20), 21q21 (rs7281081, P = 4.98 ×
10−6, OR = 0.79), and 22q12 (rs1580226, P = 8.26 × 10−6,
OR = 0.82). Subsequently, conditional analysis for secondary
signal detection was performed in all the 11 non-MHC loci by
fitting the primary SNP as a fixed effect. After conditioning
on these SNPs, no residual association was seen in these loci
(P < 1 × 10−4), indicating no evidence in the current study
for any secondary signal at these loci.
Investigation of Reported AS Genes in AAU GWAS
To investigate further potential overlaps and differences
between genetic associations of AAU and AS, we examined
the associations between the causal genes of AS and AAU. AS
genetic associations that either achieved genomewide signif-
icance in individual studies or as part of a cross-disease study
of pleiotropic genes were included.24 If the reference SNP
had been genotyped or imputed in the current study, the OR
was compared directly. Where this was not the case, tagSNPs
were identified, linkage disequilibrium with the reference
SNP determined using LDlink (ldlink.nci.nih.gov), then ODs
were compared taking into account the directionality of the
linkage disequilibrium. In addition to HLA-B, ERAP1, NOS2,
and MERTK (Table 1), moderate association was observed
with SNPs in additional known AS genes at IL23R, ASAP2,
CMC1, IL12B, ZC3H12C, IL10, SP140, and PTPN2 (Supple-
mentary Table S4). Furthermore, most of them showed the
consistent direction of effect with the discoveries in AS
GWAS (Supplementary Table S4, Supplementary Fig. S2). For
example, rs11209032 in IL23R reported in AS GWAS with OR
= 1.20,18 and this study showed OR = 1.14, with concor-
dant direction of effect. In the ASAP2 locus, rs2666218 was
observed in AS with OR = 1.12, and was associated with
AAU with OR = 1.13. Moreover, the top SNP in our AAU
analyses, rs56111045, was in very strong linkage disequilib-
rium with it (D’ = 1; R2 = 0.995). These results indicate a
consistent direction of effect of ASAP2 locus in AS and AAU.
HLA Imputation and Association Analysis
To better understand the genetic basis of the MHC suscepti-
bility loci, we performed HLA imputation using SNP2HLA.29
After removing subjects with poor HLA imputation qual-
ity, 2725 patients with AS with AAU (AS+AAU+) and 3796
patients with AS without AAU (AS+AAU-) remained and
were included in the analysis of MHC susceptibility. In
total, 424 HLA alleles (including alleles at either two-digit
or four-digit resolution) and 1276 amino acid residues were
imputed. For the HLA alleles, as expected, HLA-B*27 (P =
1.86 × 10−42, OR = 2.35) was the most significantly associ-
ated allele with AAU (Table 2). The question of whetherHLA-
B*27 exerts its influence through a dominant or additive
genetic model was assessed. Results showed that homozy-
gosity for HLA-B*27 confers OR of 3.3 (95% confidence
interval [CI] = 2.45–4.45), and heterozygosity for HLA-
B*27 confers OR of 2.93 (95% CI = 2.53–3.4). This find-
ing is consistent with previous studies of AS GWAS,36,37
suggesting that HLA-B*27 homozygosity increases risk over
heterozygosity. In addition to HLA-B*27 alleles, genomewide
significant association was also observed in unconditioned
analyses with HLA-C*02 allele (Table 2), which was also
reported in AS genetics.38 Nominal associations were also
seen between AAU and previously AS-associated allele HLA-
DRB1*0103,38 which is also known to be associated with
inflammatory bowel disease.39,40 To detect whether other
HLA alleles affect AAU susceptibility independently from the
HLA-B*27, additional conditional analyses were performed.
After adjusting for the HLA-B*27 allele, the next most-
associated HLA allele was HLA-DRB1*15 (P = 8.14 × 10−5,
OR = 1.28). After conditioning on both HLA-B*27 and HLA-
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TABLE 2. Association Analysis of HLA Alleles in the Comparison of
Patients with AS with AAU versus Patients with AS without AAU
HLA Allele# Position* OR 95% CI P Value
HLA-B*27 31431272 2.35 2.08-2.66 1.86 × 10−42
HLA-B*2705 31431272 2.27 2.02-2.56 1.49 × 10−41
HLA-C*02 31346171 1.33 1.21-1.45 3.37 × 10−9
HLA-C*0202 31346171 1.33 1.21-1.45 3.37 × 10−9
HLA-C*01 31346171 1.25 1.14-1.38 4.26 × 10−6
HLA-C*0102 31346171 1.25 1.14-1.38 4.26 × 10−6
HLA-DRB1*0103 32660042 1.34 1.14-1.57 0.00044
HLA-DRB1*1501 32660042 1.23 1.09-1.39 0.00074
HLA-C*0701 31346171 0.82 0.72-0.92 0.00078
HLA-B*4402 31431272 0.79 0.68-0.91 0.0011
HLA-C*05 31346171 0.80 0.70-0.91 0.0011
HLA-C*0501 31346171 0.80 0.70-0.91 0.0011
HLA-DQB1*0602 32739039 1.22 1.08-1.38 0.0018
HLA-DRB1*15 32660042 1.21 1.07-1.37 0.0018
HLA-B*08 31431272 0.81 0.71-0.93 0.0023
HLA-B*0801 31431272 0.81 0.71-0.93 0.0023
HLA-B*44 31431272 0.84 0.75-0.95 0.0051
Adjusting for the HLA-B*27 allele
HLA-DRB1*15 32660042 1.28 1.13-1.45 8.14 × 10−5
HLA-B*07 31431272 1.30 1.13-1.50 0.00023
HLA-DPB1*03 33157346 1.16 1.04-1.29 0.0088
Adjusting for both HLA-B*27 and HLA-DRB1*15 allele
HLA-DPB1*03 33157346 1.17 1.05-1.31 0.0048
OR, odds ratio; 95% CI, 95% confidence interval.
* UCSC, human genome build 19.
# HLA allele is imputed using SNP2HLA.
DRB1*15, lead association was seen with HLA-DPB1*03 (P
= 4.83 × 10−3, OR = 1.17).
Considering amino acid residues, the most significant
association was observed for amino acid position 97 in
HLA-B (P = 6.09 × 10−43, OR = 2.36), which was also
the strongest signal seen in AS study (Supplementary
Table S5).38 Strong associations were also observed with the
amino acid positions 70, 114, 77, 69, and 67 of HLA-B but all
these signals lost significance (P > 1 × 10−5) conditioning
on amino acid position 97 (Supplementary Table S5, Supple-
mentary Table S6). After adjusting for the amino acid posi-
tion 97, the most strongly associated signals were amino acid
position 67 and 70 in HLA-B (P = 3.80 × 10−5, OR = 1.31;
P = 4.42 × 10−5, OR = 1.31) and amino acid position 71
in HLA-DRB1 (P = 8.51 × 10−5, OR = 1.28; Supplementary
Table S6).
Interactions Between ERAP1 and HLA-B27
Previous studies have observed that the association with the
nonsynonymous SNP rs30187 (p.Lys528Arg) in the ERAP1
locus is restricted toHLA-B*27-positive orHLA-B*40-positive
HLA-B27-negative patients with AS.36,38 To assess the gene-
gene interactions between ERAP1 and HLA-B27 in AAU, we
investigated the associations by conducting two different
comparisons. In the comparison between HLA-B*27-positive
AS+AAU+ subjects and all AS+AAU- subjects, we observed
significant association with rs30187 in ERAP1 (P = 1.4 ×
10−8, OR = 1.25). However, when we compared the HLA-
B*27-negative AS+AAU+ subjects with all AS+AAU- subjects
(n = 3796) or patients with HLA-B27-negative AS+AAU- (n
= 927), we saw no association with rs30187 (P > 0.05).
These observations further support the existence of an inter-
action between ERAP1 and HLA-B27. The study did not have
sufficient power to test the interaction between HLA-B40
and ERAP1 variants so this was not performed.
eQTL Mendelian Randomization Analysis
To determine the most likely causal genes at associated
loci, we performed the SMR32 analysis for AAU with
eQTL data. GWAS data consisted of 2752 patients with AS
with AAU (AS+AAU+) and 3836 patients with AS without
AAU (AS+AAU-), and the eQTL data was from the CAGE,
which comprises individual-level whole-blood expression
and genotype data on 2765 individuals.33 In the SMR analy-
sis, only probes for which the P value of the top associated
cis-eQTL was < 5 × 10−8 were included and the MHC region
was excluded. To control the genomewide type I error rate,
Bonferroni correction was used to account for multiple test-
ing, which resulted in a genomewide significance level of P
= 5.95 × 10−6 (= 0.05/8403).
Results of top signals are summarized in Table 3. Notably,
the most significant signal was ERAP1 (PGWAS = 7.91 ×
10−7, PeQTL = 4.71 × 10−83, PSMR = 1.75 × 10−6), which
reached genomewide significance (Table 3 and Fig. 3). In
addition to ERAP1, the most associated gene was MERTK
(PGWAS = 3.95 × 10−5, PeQTL = 4.02 × 10−73, PSMR = 6.25
× 10−5) which was very close to genomewide significance
(Table 3 and Fig. 4). These findings indicate that ERAP1 and
MERTK are the most functionally relevant genes in these two
loci.
Estimation of SNP-Based Heritability
Heritability is the proportion of the phenotypic variance
accounted for by genetic effects. We investigated SNP-based
heritability by designing three different comparisons: (1)
patients with AS with AAU versus AS alone; (2) patients with
AS alone versus controls; and (3) patients with AS with AAU
versus controls. The details are summarized in Table 4. The
estimation of heritability was 0.40 to 0.43 in the comparison
between patients with AS with AAU and patients with AS
without AAU, adjusting prevalence from 0.3 to 0.5. Interest-
ingly, in the comparison between AS alone and controls, the
estimated heritability was 0.48 to 0.60, adjusting prevalence
from 0.002 to 0.006. When we compared the patients with
AS and with AAU to controls, the estimated heritability was
0.59 to 0.72, adjusting prevalence from 0.001 to 0.003. These
discoveries not only confirmed that AS and AAU are highly
heritably disorders, but also suggest that there are additional
genetic contributors to AAU compared with AS alone.
Genetic Risk Prediction
The greater heritability of AS+AAU+ compared with AS
alone or AS+AAU- suggests that PRS have the potential to
identify AAU cases likely to develop AS, and conversely
AS cases likely to develop AAU. To assess the discrimi-
natory capacity and accuracy in risk prediction, we first
performed the analyses of PRS by using two different
designs (1) AS+AAU+ versus AS+AAU-; and (2) AS+AAU+
versus controls. In the first comparison, AS+AAU+ versus
AS+AAU-, the overall discriminatory capacity of PRS was
weak (AUC = 0.56; 95% CI = 0.54–0.58; P value = 2.10 ×
10−10). Assuming the prevalence of patients with AS with
AAU is 40% among the AS population, those patients with
AS in the top 50% of genetic risk had an estimated genetic
risk of developing AAU of 43.3% (SD = 0.9%; Supplemen-
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FIGURE 3. Locus zoom plot of SMR analysis for ERAP1 locus. Top plot, grey dots represent the P values for SNPs from the comparison
between AS+AAU+ and AS+AAU-, diamonds represent the P values for probes from the SMR test. Bottom plot, the eQTL P values of SNPs
from the CAGE study for the ILMN_2336220 probe tagging ERAP1.
FIGURE 4. Locus zoom plot of SMR analysis for MERTK locus. Top plot, grey dots represent the P values for SNPs from the comparison
between AS+AAU+ and AS+AAU-, diamonds represent the P values for probes from the SMR test. Bottom plot, the eQTL P values of SNPs
from the CAGE study for the ILMN_2138589 probe tagging MERTK.
tary Fig. S3). Those in the bottom 50% had < 37% chance
of developing the disease. Thus, in the setting of a patient
with AS, PRS alone are currently not helpful in distinguish-
ing those patients likely to develop AAU.
In the second comparison, AS+AAU+ versus controls, we
observed the overall discriminatory capacity of genomewide
PRS was very strong (AUC = 0.96; 95% CI = 0.955–0.966).
When computing PRS using HLA-B27 alone, the AUC is 0.92
TABLE 4. Estimation of Heritability in Three Comparisons
Cases (Number) Controls (Number) Heritability* (SE; Adjusted Prevalence)
AS+AAU+ (2752) AS+AAU− (3836) 0.40 (0.071; 0.3) 0.42 (0.075; 0.4) 0.43 (0.077; 0.5)
AS+AAU− (3836) Controls (14542) 0.48 (0.008; 0.002) 0.55 (0.010; 0.004) 0.60 (0.010; 0.006)
AS+AAU+ (2752) Controls (14542) 0.59 (0.009; 0.001) 0.67 (0.010; 0.002) 0.72 (0.011; 0.003)
* Heritability is calculated using GCTA (https://cnsgenomics.com/software/gcta/#Download).
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FIGURE 5. Positive and negative predictive values for patients with AS with AAU for centiles of genetic risk scores. The assumed prevalence
of patients with AS with AAU of 0.3% among the population (a), and assumed prevalence of 20% in outpatient clinics (b). Error Bars denote
2 standard deviations based on 10-fold cross validation.
(95% CI = 0.915–0.927). Considering a general population
setting, assuming the prevalence of patients with AS with
AAU is 0.3% among the population, those in the top 10% of
genetic risk had an estimated genetic risk of developing AS
with AAU of 10.1% (SD = 0.9%; Fig. 5a), 2.9 times higher than
the risk using HLA-B27 alone (3.5% [SD = 0.1%], Supplemen-
tary Fig. S4a). Those in the top 5% had a risk of developing
AS with AAU of 14.3% (SD = 1.9%; Fig. 5a), 3.6 × higher than
the risk estimate using HLA-B27 alone (4% [SD = 0.4%]).
Those in the bottom 85% had < 0.1% chance of developing
the disease, similar to the estimate using HLA-B27 alone.
Considering a clinical setting where patients with AAU are
being assessed for their risk of AS, assuming the prevalence
of patients with AS with AAU is 20% in outpatient clinics, we
observed the estimated genetic risk of developing disease of
90.3% (SD = 0.8%) for those in the top 10% and 93.2% (SD
= 1.0%) for those in the top 5% (Fig. 5b). Using HLA-B27
alone, the estimated genetic risk of developing disease of
75.2% (SD = 0.9%) for those in the top 10% and 77.3% (SD =
1.9%). Considering negative predictive values, using the PRS
the bottom 65% of patients would have < 1% chance of also
having AS. The performance using a score for HLA-B27 alone
is marginally worse, with the maximum negative predictive
value (NPV) being 98%, 75% of the distribution (Supplemen-
tary Fig. S4b). These results indicate that genomewide PRS
has better performance than HLA-B27 alone, particularly in
positive predictive value (PPV) analyses.
DISCUSSION
This study has expanded understanding of the genetics of
AAU, through the discovery of novel suggestive associated
loci including MERTK, CLCN7, ACAA2, KIFAP3, and five
intergenic loci. Among those new loci, MERTK locus is also
a novel finding in our ongoing GWAS in AS. Interestingly,
Mendelian randomization analysis for AAU with eQTL data
showed that MERTK is the most functionally relevant gene
in the locus.
MERTK is a member of the TYRO3/AXL/MER (TAM)
receptor kinase family and encodes a transmembrane
protein, which has fibronectin type-III domains, two
immunoglobulin-like (Ig-like) C2-type domains, and one
tyrosine kinase domain.41 The three TAM receptors inter-
act functionally with one another in their pleiotropic roles
in immune regulation, including in autoimmune and infec-
tious diseases, and cancer.42 MERTK was not previously
known to be associated with AS or AAU, whereas muta-
tions in MERTK gene lead to an inherited retinal disorder,
named retinitis pigmentosa.41 Notably, mutations in previ-
ously reported AAU-related gene EYS also lead to retinitis
pigmentosa.9,43 In addition to retinitis pigmentosa, genetic
associations of MERTK have also been reported in a few
other traits. SNP associations with SNPs in linkage dise-
quilibrium with the strongest associated SNP in AAU have
previously been reported in multiple sclerosis and systolic
blood pressure (r2 > 0.5, both concordant in direction), and
with other SNPs not in linkage disequilibrium (r2 < 0.3)
with rs10171979, including hepatitis C induced liver fibro-
sis, coronary artery disease, heel bone mineral density, and
white blood cell count (https://www.ebi.ac.uk/gwas/genes/
MERTK). Axl/Mertk double knockout mice are susceptible to
T-cell mediated uveitis,44 and Tyro3/Axl/Mertk triple knock-
out mice develop bone marrow edema and macrophage and
B-cell and T-cell infiltration, consistent with changes seen
in spondyloarthritidies.45 MERTK is expressed at high levels
in the ovaries, prostate, testis, lungs, retinas, and kidneys,
and at lower levels in the heart, brain, and skeletal muscle.46
MERTK is also expressed in macrophages, dendritic cells,
natural killer (NK) cells, NKT cells, and platelets.46–48 MERTK
is not expressed on the normal lymphocytes but has
been found to be expressed in a majority of lymphoblasts
from patients with T-cell leukemia, certain subsets of B-
cell leukemia, and mantle cell lymphoma.49,50 Addition-
ally, MERTK signaling plays a role in various processes,
such as macrophage clearance of apoptotic cells, platelet
aggregation, cytoskeleton reorganization, and engulfment.
Animal models that lack functional MERTK protein have
macrophages that are unable to appropriately engulf apop-
totic cells. This inefficient clearance of dead cells can lead
to activation of inflammation and development of autoim-
munity.51 Moreover, MERTK was also reported as a potent
suppressor of T cell response.52 Taken together, these
discoveries indicate the potential role of MERTK in the etiol-
ogy of AAU. However, the functional relevance in this study
was based on gene expression and did not include other
functions. Future functional studies are necessary to further
understand the biological mechanisms underpinning the
association of MERTK with AAU.
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This study also confirmed multiple discoveries from
previous genetics of AS/AAU. We confirmed the associ-
ation of previously reported loci associated with AAU
from a large genetic study on the basis of immunochip
genotyping, including HLA-B, ERAP1, IL23R, and IL10.9
We also confirmed the association of previously reported
genetic loci associated with AS but not yet with AAU, includ-
ing NOS2, ASAP2, CMC1, IL12B, ZC3H12C, SP140, and
PTPN2. Furthermore, consistent with previous studies on
MHC loci of AS/AAU, HLA imputation of this study showed
that HLA-B*27 was the most significantly associated allele
with AAU (Supplementary Fig. S5a), and we also observed
HLA-B*27 homozygosity increases risk over heterozygosity.
We also confirmed the existence of an interaction between
ERAP1 and HLA-B*27 for AAU, which was initially discov-
ered in a GWAS of AS. Minor additional risk association was
seen with HLA-DRB1*15 (Supplementary Fig. S5b), consis-
tent with previous reports using direct genotyping,53 and
with HLA-DPB1*03 (Supplementary Fig. S5c), independent
of HLA-B27, suggesting the presence of additional MHC
encoded factors influencing AAU risk in patients with AS.
We have estimated SNP-based heritability in different
comparisons, and found both patients with AS alone and
patients with AS and with AAU showed high heritability. The
estimations of heritability based on genotyped SNPs reached
approximately 0.7, which is very close to the result from
twin studies for AS alone (heritability > 0.9).54,55 Moreover,
the AS+AAU+ cohort showed higher heritability than the
AS+AAU- cohort, indicating that AAU cases carry additional
genetic risk compared with cases with isolated AS. This
supports further initiatives to identify AAU genetic suscepti-
bility factors.
To assess the discriminatory capacity and accuracy in risk
prediction using genomewide PRS, we first applied PRS on
subjects with AS+AAU+ versus subjects with AS alone. But
the overall discriminatory capacity of this PRS (AUC = 0.56)
was too low to be of clinical utility. Subsequently, we applied
PRS on subjects with AS+AAU+ versus controls. Interest-
ingly, we observed the discriminatory capacity of PRS was
very strong with AUC of 0.96, and higher than the discrimi-
natory capacity of HLA-B27 alone (AUC = 0.92). The differ-
ence in performance of the PRS and HLA-B27 alone is more
apparent when PPV and NPVs are considered. As HLA-B27 is
only carried in approximately 8% of European-descent popu-
lations, it can only demonstrate increased risk in that small
group, and provides no information about the relative risk of
the disease across the remaining 92% of the population. In
contrast, not only does the PRS provide higher PPVs even
among HLA-B27 positive individuals, it also is informative
about differences in AAU risk across HLA-B27 negative indi-
viduals. PRS also performed significantly better in exclud-
ing AS among patients with AAU than did HLA-B27 alone.
These results suggest that PRS has significant potential clini-
cal benefit in predicting the likelihood of developing AS with
AAU, although it had limited capacity in risk prediction of
the patients with AS developing AAU.
The prevalence of AAU increases almost linearly with
increasing disease duration, with over 50% of patients with
AS with > 40 years of disease duration having experienced
AAU.9 Thus, it is likely that many patients classified in the
current study as not being AAU affected will ultimately likely
develop the complication. This reduces the power to detect
genetic associations, to identify heritability, and to develop
PRS. A further complication is the need to use study designs
controlling for fact that these patients have an additional
highly heritable disease, AS. The study design, therefore, is
only able to distinguish factors that influence the risk of AAU
over and above their effect on the risk of AS. Thus genetic
effects on risk of AAU that are shared at similar strengths
with AS will not be detected by this study design. Such asso-
ciations could potentially be identified in studies compar-
ing AAU cases not affected by AS with controls. However,
the high prevalence of AS among AAU cases, and the high
frequency of subclinical sacroiliitis in these patients, would
mean that careful screening of cases would be required, and
that cases would need to be old enough that AS would be
unlikely to develop in the future if it had not already mani-
fested. We also acknowledge the limitation of our study of
lack of independent replication to test the observed associa-
tions across multiple cohorts. Future studies should consider
our GWAS findings in different populations.
In conclusion, we report here the first GWAS for AAU
and identified new susceptibility loci. The findings of asso-
ciation with the HLA-B, ERAP1, NOS2, and IL23R loci are
consistent with a strong overlap in etiopathogenesis with
AS. We identified new suggestive associated loci of AAU,
including MERTK, which was reported to be involved in
the development of autoimmunity, indicating the potential
role of MERTK in the etiology of AAU. Further research is
needed into the immunopathogenic mechanisms of AAU and
AS. Investigation of genomewide polygenic risk scores of AS
alone and AS with AAU both showed strong discriminatory
capacity and high accuracy in risk prediction. Our findings
suggest PRS based on GWAS data can quantify individual AS
and AAU risks in clinically significant ways, potentially lead-
ing to the effective implementation of genetic discoveries in
healthcare applications.
Acknowledgments
The authors thank all participating subjects with AS and
healthy individuals who provided the DNA and clinical infor-
mation necessary for this study. We would like to acknowledge
the contributions of Anna Deminger, Sahlgrenska Academy at
University of Gothenburg, and Urban Hellman, Umeå Univer-
sity, for their assistance in case recruitment and assessment and
handling biological samples.
X.F.H. was funded by the National Natural Science Founda-
tion of China (31771390). The TASC study was funded by the
National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) grants P01-052915, R01-AR046208. Fund-
ing was also received from the University of Texas Health
Science Center at Houston CTSA grant UL1RR02418, Cedars-
Sinai GCRC grant MO1-RR00425, Intramural Research Program,
NIAMS/NIH, and Rebecca Cooper Foundation (Australia).
This study was funded, in part, by Arthritis Research UK
(Grants 19536 and 18797), by the Wellcome Trust (Grant
number 076113), and by the Oxford Comprehensive Biomedical
Research Centre ankylosing spondylitis chronic disease cohort
(Theme Code: A91202). The New Zealand data was derived from
participants in the Spondyloarthritis Genetics and the Environ-
ment Study (SAGE) and was funded by The Health Research
Council, New Zealand. H.X. was funded by the National
Natural Science Foundation of China Grant 81020108029 and
30872339. French sample collection was performed by the
Groupe Française d’Etude Génétique des Spondylarthrites, coor-
dinated by Professor Maxime Breban, and funded by the Agence
Nationale de Recherche GEMISA grant reference ANR-10-MIDI-
0002. We acknowledge the Understanding Society: The UK
Household Longitudinal Study. This is led by the Institute
for Social and Economic Research at the University of Essex
and funded by the Economic and Social Research Council.
Downloaded from iovs.arvojournals.org on 05/19/2021
GWAS of AAU IOVS | June 2020 | Vol. 61 | No. 6 | Article 3 | 11
The survey was conducted by NatCen and the genomewide
scan data were analyzed and deposited by the Wellcome Trust
Sanger Institute. Information on how to access the data can
be found on the Understanding Society website https: www.
understandingsociety.ac.uk/ . We acknowledge and thank the
TCRA AS Group for their support in recruiting patients for
the study. M.A.B. is funded by a National Health and Medical
Research Council (Australia) Senior Principal Research Fellow-
ship, and support for this study was received from a National
Health and Medical Research Council (Australia) program Grant
(566938) and project Grant (569829), and from the Australian
Cancer Research Foundation and Rebecca Cooper Medical
Research Foundation. We are also very grateful for the invalu-
able support received from the National Ankylosing Spondylitis
Society (UK) and Spondyloarthritis Association of America in
case recruitment. Additional financial and technical support for
patient recruitment was provided by the National Institute for
Health Research Oxford Musculoskeletal Biomedical Research
Unit and NIHR Thames Valley Comprehensive Local Research
and an unrestricted educational grant from Abbott Laborato-
ries. The authors acknowledge the sharing of data and samples
by the BSRBR-AS Register in Aberdeen. Chief Investigator, Prof
Gary Macfarlane and Dr Gareth Jones, Deputy Chief Investiga-
tor, created the BSRBR-AS study, which was commissioned by
the British Society for Rheumatology, funded in part by Abbvie,
Pfizer, and UCB. We are grateful to every patient, past and
present staff of the BSRBR-AS register team, and to all clini-
cal staff who recruited patients, followed them up and entered
data – details here: https://www.abdn.ac.uk/iahs/research/
epidemiology/spondyloarthritis.php#panel1011. Funding was
also received from the Swedish Research Council and The
Swedish state under the agreement between the Swedish
government and the county councils, the ALF agreement. The
Irish data was derived from participants in ASRI – The Anky-
losing Spondylitis Registry of Ireland, which is funded by unre-
stricted grants from Abbvie and Pfizer. Funding bodies involved
played no role in the study design, performance, or preparation
of this manuscript.
Disclosure: X.-F. Huang, None; Z. Li, None; E. De Guzman,
None; P. Robinson, None; L. Gensler, None; M.M.Ward, None;
M.H. Rahbar, None; M. Lee, None; M.H. Weisman, None;
G.J. Macfarlane, None; G.T. Jones, None; E. Klingberg, None;
H. Forsblad-d’Elia, None; P. McCluskey, None; D. Wakefield,
None; J.S. Coombes, None; M.A. Fiatarone Singh, None; Y.
Mavros, None; N. Vlahovich, None; D.C. Hughes, None; H.
Marzo-Ortega, None; I. Van der Horste-Bruinsma, None; F.
O’Shea, None; T.M. Martin, None; J. Rosenbaum, None; M.
Breban, None; Z.-B. Jin, None; P. Leo, None; J.D. Reveille,
None; B.P. Wordsworth, None; M.A. Brown, None
References
1. Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on
the worldwide epidemiology of uveitis. Eur J Ophthalmol.
2013;23:705–717.
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in
Northern California; the Northern California Epidemiology
of Uveitis Study. Ophthalmology. 2004;111:491–500; discus-
sion 500.
3. Nakao K, Ohba N. [Prevalence of endogenous uveitis in
Kagoshima Prefecture, Southwest Japan]. Nippon Ganka
Gakkai Zasshi. 1996;100:150–155.
4. Dandona L, Dandona R, John RK, McCarty CA, Rao GN.
Population based assessment of uveitis in an urban popula-
tion in southern India. Br J Ophthalmol. 2000;84:706–709.
5. D’Ambrosio EM, La Cava M, Tortorella P, Gharbiya M,
Campanella M, Iannetti L. Clinical features and complica-
tions of the HLA-B27-associated acute anterior uveitis: a
metanalysis. Semin Ophthalmol. 2017;32:689–701.
6. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis
and HLA-B27. Surv Ophthalmol. 2005;50:364–388.
7. Monnet D, Breban M, Hudry C, Dougados M, Brezin AP.
Ophthalmic findings and frequency of extraocular mani-
festations in patients with HLA-B27 uveitis: a study of 175
cases. Ophthalmology. 2004;111:802–809.
8. Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC.
Acute anterior uveitis and HL-A 27. Lancet. 1973;302:994–
996.
9. Robinson PC, Claushuis TA, Cortes A, et al. Genetic dissec-
tion of acute anterior uveitis reveals similarities and differ-
ences in associations observed with ankylosing spondylitis.
Arthritis Rheumatol. 2015;67:140–151.
10. Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus
on the epidemiology of uveitis. Ocul Immunol Inflamm.
2018;26:2–16.
11. Derhaag PJ, Linssen A, Broekema N, de Waal LP, Feltkamp
TE. A familial study of the inheritance of HLA-B27-positive
acute anterior uveitis. Am J Ophthalmol. 1988;105:603–606.
12. Robinson PC, Leo PJ, Pointon JJ, et al. The genetic asso-
ciations of acute anterior uveitis and their overlap with
the genetics of ankylosing spondylitis. Genes Immun.
2016;17:46–51.
13. Huang XF, Chi W, Lin D, et al. Association of IL33 and
IL1RAP polymorphisms with acute anterior uveitis.CurrMol
Med. 2018;17:471–477.
14. Li H, Hou S, Yu H, et al. Association of genetic variations in
TNFSF15 with acute anterior uveitis in Chinese Han. Invest
Ophthalmol Vis Sci. 2015;56:4605–4610.
15. Wang Y, Huang XF, Yang MM, et al. CFI-rs7356506 is a
genetic protective factor for acute anterior uveitis in Chinese
patients. Br J Ophthalmol. 2014;98:1592–1596.
16. Burton PR, Clayton DG, Cardon LR, et al. Association
scan of 14,500 nonsynonymous SNPs in four diseases
identifies autoimmunity variants. Nat Genet. 2007;39:1329–
1337.
17. Reveille JD, Sims AM, Danoy P, et al. Genome-wide asso-
ciation study of ankylosing spondylitis identifies non-MHC
susceptibility loci. Nat Genet. 2010;42:123–127.
18. Evans DM, Spencer CCA, Pointon JJ, et al. Interaction
between ERAP1 and HLA-B27 in ankylosing spondyli-
tis implicates peptide handling in the mechanism for
HLA-B27 in disease susceptibility. Nat Genet. 2011;43:761–
767.
19. Cortes A, Hadler J, Pointon JP, et al. Identification of
multiple risk variants for ankylosing spondylitis through
high-density genotyping of immune-related loci. Nat Genet.
2013;45:730–738.
20. Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five
chronic inflammatory diseases identifies 27 new associa-
tions and highlights disease-specific patterns at shared loci.
Nat Genet. 2016;48:510–518.
21. Ranganathan V, Gracey E, Brown MA, Inman RD,
Haroon N. Pathogenesis of ankylosing spondylitis - recent
advances and future directions.Nat Rev Rheumatol. 2017;13:
359–367.
22. Brown MA. Breakthroughs in genetic studies of anky-
losing spondylitis. Rheumatology (Oxford). 2008;47:
132–137.
23. Visscher PM, Wray NR, Zhang Q, et al. 10 Years of GWAS
discovery: biology, function, and translation. Am J Hum
Genet. 2017;101:5–22.
24. Brown MA, Wordsworth BP. Genetics in ankylosing
spondylitis - current state of the art and translation into clin-
ical outcomes. Best Pract Res Clin Rheumatol. 2017;31:763–
776.
25. van der Linden S, Valkenburg HA, Cats A. Evaluation of
diagnostic criteria for ankylosing spondylitis. A proposal
Downloaded from iovs.arvojournals.org on 05/19/2021
GWAS of AAU IOVS | June 2020 | Vol. 61 | No. 6 | Article 3 | 12
for modification of the New York criteria. Arthritis Rheum.
1984;27:361–368.
26. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool
for genome-wide complex trait analysis. Am J Hum Genet.
2011;88:76–82.
27. Loh PR, Danecek P, Palamara PF, et al. Reference-based
phasing using the Haplotype Reference Consortium panel.
Nat Genet. 2016;48:1443–1448.
28. Durbin R. Efficient haplotype matching and storage using
the positional Burrows-Wheeler transform (PBWT). Bioin-
formatics. 2014;30:1266–1272.
29. Jia X, Han B, Onengut-Gumuscu S, et al. Imputing amino
acid polymorphisms in human leukocyte antigens. PLoS
One. 2013;8:e64683.
30. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set
for whole-genome association and population-based link-
age analyses. Am J Hum Genet. 2007;81:559–575.
31. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional
visualization of genome-wide association scan results.
Bioinformatics. 2010;26:2336–2337.
32. Zhu Z, Zhang F, Hu H, et al. Integration of summary data
from GWAS and eQTL studies predicts complex trait gene
targets. Nat Genet. 2016;48:481–487.
33. Lloyd-Jones LR, Holloway A, McRae A, et al. The genetic
architecture of gene expression in peripheral blood. Am J
Hum Genet. 2017;100:228–237.
34. Speed D, Balding DJ. MultiBLUP: improved SNP-based
prediction for complex traits. Genome Res. 2014;24:1550–
1557.
35. Leo PJ, Madeleine MM, Wang S, et al. Defining the genetic
susceptibility to cervical neoplasia-A genome-wide associa-
tion study. PLoS Genet. 2017;13:e1006866.
36. Evans DM, Spencer CC, Pointon JJ, et al. Interaction between
ERAP1 and HLA-B27 in ankylosing spondylitis implicates
peptide handling in the mechanism for HLA-B27 in disease
susceptibility. Nat Genet. 2011;43:761–767.
37. International Genetics of Ankylosing Spondylitis Consor-
tium (IGAS),Cortes A, Hadler J, et al. Identification of
multiple risk variants for ankylosing spondylitis through
high-density genotyping of immune-related loci. Nat Genet.
2013;45:730–738.
38. Cortes A, Pulit SL, Leo PJ, et al. Major histocompatibility
complex associations of ankylosing spondylitis are complex
and involve further epistasis with ERAP1. Nat Commun.
2015;6:7146.
39. Silverberg MS, Mirea L, Bull SB, et al. A population- and
family-based study of Canadian families reveals association
of HLA DRB1*0103 with colonic involvement in inflamma-
tory bowel disease. Inflamm Bowel Dis. 2003;9:1–9.
40. Lappalainen M, Halme L, Turunen U, et al. Association
of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants
with inflammatory bowel disease phenotypes in the Finnish
population. Inflamm Bowel Dis. 2008;14:1118–1124.
41. Gal A, Li Y, Thompson DA, et al. Mutations in MERTK, the
human orthologue of the RCS rat retinal dystrophy gene,
cause retinitis pigmentosa. Nat Genet. 2000;26:270–271.
42. Lemke G. Biology of the TAM receptors. Cold Spring Harb
Perspect Biol. 2013;5:a009076.
43. Abd El-Aziz MM, Barragan I, O’Driscoll CA, et al. EYS,
encoding an ortholog of Drosophila spacemaker, is mutated
in autosomal recessive retinitis pigmentosa. Nat Genet.
2008;40:1285–1287.
44. Ye F, Li Q, Ke Y, et al. TAM receptor knockout mice
are susceptible to retinal autoimmune induction. Invest
Ophthalmol Vis Sci. 2011;52:4239–4246.
45. Waterborg CEJ, Koenders MI, van Lent P, van der Kraan PM,
van de Loo FAJ. Tyro3/Axl/Mertk-deficient mice develop
bone marrow edema which is an early pathological marker
in rheumatoid arthritis. PLoS One. 2018;13:e0205902.
46. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR,
Earp HS. Cloning and mRNA expression analysis of a
novel human protooncogene, c-mer. Cell Growth Differ.
1994;5:647–657.
47. Behrens EM, Gadue P, Gong SY, Garrett S, Stein PL, Cohen
PL. The mer receptor tyrosine kinase: expression and func-
tion suggest a role in innate immunity. Eur J Immunol.
2003;33:2160–2167.
48. Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Defi-
ciency or inhibition of Gas6 causes platelet dysfunction and
protects mice against thrombosis. Nat Med. 2001;7:215–221.
49. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification,
subtype discovery, and prediction of outcome in pediatric
acute lymphoblastic leukemia by gene expression profiling.
Cancer Cell. 2002;1:133–143.
50. Graham DK, Salzberg DB, Kurtzberg J, et al. Ectopic expres-
sion of the proto-oncogene Mer in pediatric T-cell acute
lymphoblastic leukemia. Clin Cancer Res. 2006;12:2662–
2669.
51. Scott RS, McMahon EJ, Pop SM, et al. Phagocytosis and
clearance of apoptotic cells is mediated by MER. Nature.
2001;411:207–211.
52. Cabezon R, Carrera-Silva EA, Florez-Grau G, et al. MERTK
as negative regulator of human T cell activation. J Leukoc
Biol. 2015;97:751–760.
53. Reveille JD, Zhou X, Lee M, et al. HLA class I and II alleles
in susceptibility to ankylosing spondylitis. Ann Rheum Dis.
2019;78:66–73.
54. Brown MA, Kennedy LG, MacGregor AJ, et al. Suscep-
tibility to ankylosing spondylitis in twins: the role of
genes, HLA, and the environment.Arthritis Rheum. 1997;40:
1823–1828.
55. Pedersen OB, Svendsen AJ, Ejstrup L, Skytthe A, Harris JR,
Junker P. Ankylosing spondylitis in Danish and Norwegian
twins: occurrence and the relative importance of genetic
vs. environmental effectors in disease causation. Scand J
Rheumatol. 2008;37:120–126.
Downloaded from iovs.arvojournals.org on 05/19/2021
